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N-glycosylation of proteins in endoplasmic reticulum is critical for protein quality control. We showed here
a post-translational N-glycosylation affected by the HRD1 E3 ubiquitin ligase. Both WT- and E3-defective
C329S-HRD1 decreased the level of high mannose form of ABCG8, a protein that heterodimerizes with
ABCG5 to control sterol balance. Meanwhile, HRD1 increased the non-glycosylated ABCG8 regardless of its
E3 activity, thereby suppressing full maturation of ABCG5/8 transporter. Pulse chase and mutational
analysis indicated that HRD1 inhibits STT3B-dependent post-translational N-glycosylation of ABCG8.
Whereas, HRD1 had only slight effect on the N-glycosylation status of ABCG5; rather it accelerated ABCG5
degradation in an E3 activity-dependent manner. Finally, RMA1, another E3 ubiquitin ligase, accelerated
the degradation of both ABCG5 and ABCG8 via E3 activity-dependent manner. HRD1 and RMA1 may
therefore be negative regulators of disease-associated transporter ABCG5/ABCG8. The findings also
highlight the unexpected E3 activity-independent role of HRD1 in the regulation of N-glycosylation.
T
he secretory pathway in eukaryotic cells is accompanied by a variety of covalent modifications to the
polypeptides that are newly synthesized in endoplasmic reticulum (ER)1. Among the modifications of
secretory proteins, asparagine (N)-linked glycosylation (N-glycosylation) catalyzed by the oligosaccharyl-
transferase (OST) complex is one of the major modifications of both soluble and membrane-spanning proteins2.
The N-glycans on the proteins contribute to their proper folding, assembly and stability due to their physical
properties as well as to the quality control by serving as a ‘tag’ for glycoproteins to be recognized by molecular
chaperones, or otherwise targeted for the ER-associated degradation (ERAD)2. Hence, understanding how
balance of protein N-linked glycosylation and de-glycosylation is regulated has been an important issue in recent
years.
In general, N-glycosylation of secretory proteins is an event that occurs co-translationally. After nascent
polypeptide enters ER lumen, the OST complex recognizes the sequon, Asn-X-Thr/Ser (where X can be any
amino acid other than proline)3 and transfers the high mannose oligosaccharides co-translationally as long as the
sequon is 65–75 residues away from the peptidyl-transferase site on the large ribosomal subunit4. STT3A, a major
catalytic subunit of OST complex, is considered to be primarily responsible for the co-translational N-glycosyla-
tion of both soluble and membrane-spanning proteins5. Importantly, others and we recently identified the novel
type of N-glycosylation that occurs post-translationally. The examples of post-translationally N-glycosylated
proteins are yet limited to a few cases such as human coagulation factor VII (FVII)6 and excessively unfolded
human transthyretin (TTR)7. Notably, in these cases, another STT3 isoform STT3B is considered as an important
factor to mediate post-translational N-glycosylation in the OST complex.
Human ATP-binding cassette transporters (ABC transporters) are membrane transporters that use energy
from ATP hydrolysis to transport a wide variety of substrates across the cellular membrane8. ABC transporters are
classified as either full transporter containing two transmembrane domains (TMDs) and two nucleotide binding
domains (NBDs) or as half transporters containing one of each domain8. Full transporters generally function as a
monomer, while half transporters assemble as either homodimers or heterodimers to create a functional trans-
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post-translational mechanisms. Among these, studies on post-trans-
lational regulation, especially N-linked glycosylation-dependent
regulation, have been increasingly given attention because most of
ABC transporters possess putative modification sequon for N-gly-
cosylation9,10. However, how N-glycosylation of these multi-span-
ning membrane transporters is physiologically controlled and
factors that are involved in the regulation are yet to be fully
understood.
One of the clinically relevant ABC transporters, whose intracellu-
lar quality control system is only identified in mice11–13, is the
ABCG5/ABCG8 complex, both of which are ABC half-transporters
that are highly expressed in the apical membranes of small intestine
and the canalicular membranes in liver. Murine ABCG5 and ABCG8
form heterodimer in ER and are expressed to the plasma membrane,
where they work as a sterol transporter11. Defect in plasma mem-
brane expression of ABCG5/8 complex results in a genetic disorder
called sitosterolemia as well as severe premature atherosclerosis14,15,
implying that monitoring the quality of ABCG5 and ABCG8 pro-
teins is critical for the regulation of their functional expression in the
cells. Although, like other ABC transporters, two and one N-glyco-
sylation sites exist in murine ABCG5 and ABCG8, respectively12, the
physiological relevance of N-glycosylation of human ABCG5 and
ABCG8, especially the sites for N-glycosylation and the factors that
regulate the N-glycosylation, are still unknown.
Here, we established expression system of human ABCG5 and
ABCG8 proteins and determined the sites for N-glycosylation.
Unexpectedly, the N-glycosylation sites for ABCG5 and ABCG8
were mostly post-translationally modified and STT3B is robustly
involved in the post-translational N-glycosylation of ABCG8.
HRD1 E3 ubiquitin ligase, regardless of its E3 ligase activity, inhib-
ited the STT3B-dependent N-glycosylation of ABCG8, thereby
destabilizing ABCG8 protein. Despite the strong effect of HRD1
on ABCG8, HRD1 accelerated ABCG5 degradation in an E3 activ-
ity-dependent manner but had only slight effect on the N-glycosyla-
tion status of ABCG5. Another E3 ubiquitin ligase RMA1 accelerated
the degradation of both ABCG5 and ABCG8 without any effects on
N-glycosylation status in an E3-dependent manner. Our results are
the first to show an example of post-translational N-glycosylation of
multi-spanning membrane glycoprotein and provide an unexpected
role of HRD1 in the post-translational N-glycosylation that affects
protein stability. Overall, we clearly indicate the molecular basis of
HRD1- and RMA1-dependent negative regulation of disease-assoc-
iated transporter ABCG5/ABCG8.
Results
Determination of band patterns of monomeric and heterodimeric
human ABCG5 and ABCG8. To confirm the expression patterns of
monomeric and heterodimeric human ABCG5 and/or ABCG8, we
first expressed Myc-tagged ABCG5 (Myc-ABCG5) or HA-tagged
ABCG8 (HA-ABCG8) in HEK293 cells. The isolated cell lysates
were then subjected to treatment with different endoglycosidases.
Both ABCG5 and ABCG8 were detected as 65-kDa and 63-kDa
protein bands, respectively (Supplementary Figure S1a, lanes 1–2,
4–5; S1c,d; S2; S3). These bands were sensitive not only to PNGase
F, which removes all N-linked sugars, but also to Endo H, which
removes high-mannose sugars that have not yet undergone full
maturation (Supplementary Figure S1c,d, non-glycosylated (Non-
G) forms; S4), suggesting that the original bands derived from
single expression represent ER-localized high mannose (HM)
forms of ABCG5 and ABCG8 proteins, as is often the case with
previous study11,12. We next sought to determine whether these
molecules properly heterodimerize when coexpressed in the cells.
As shown in Supplementary Figure S1a (Lane 6), S1b (lane 4), S2
and S3, coexpression of Myc-ABCG5 and HA-ABCG8 resulted in
the appearance of additional high molecular weight (HMW) forms
that are indicated as complex glycosylated (C-G) forms, which are
considered to localize in the golgi or plasma membrane (ABCG5, 70-
to 76-kDa; ABCG8, 68- to 74-kDa). Consistently, these HMW
protein bands were sensitive to PNGase F, but were resistant to
Endo H (Supplementary Figure S1b, lanes 5–6; S3), confirming the
existence of heterodimeric human ABCG5/ABCG8 complex in
coexpression condition, consistent with previous reports11,12.
Determination of N-linked glycosylation sites in human ABCG5
and ABCG8. To determine N-glycosylation sites of human ABCG5
and ABCG8, we performed characterization of non-glycosylation
mutants of these proteins. We took advantage of previous report on
the N-glycosylation sites of murine ABCG5 at residue 585 and 592,
and murine ABCG8 at residue 61912 since the sites are conserved
between mice and human (Figure 1a, at residue 584 and 591 in
human; 1d, at residue 619 in human). Single substitution of gluta-
mine for asparagine at position 584 (N584Q) and at position 591
(N591Q) in human ABCG5 reduced the apparent molecular mass
to a similar extent between two mutants (Figure 1b). Double
mutation (N584Q/N591Q) further reduced the band size identical
to those of EndoH- and PNGase F-treated ABCG5 proteins
(Figure 1b,c; Supplementary Figure S4), indicating that human
ABCG5 contains two N-linked glycans at positions 584 and 591.
On the other hand, substitution of glutamine for asparagine at
position 619 (N619Q) of human ABCG8 also reduced the mole-
cular mass, and the band size was identical to those of EndoH- and
PNGase F-treated ABCG8 proteins (Figure 1e; Supplementary Figure
S4), demonstrating that human ABCG8 contains a single N-linked
glycan at position 619. Moreover, the steady state expression of N-
glycosylation defective mutants of human ABCG5 and ABCG8 was
lower when compared to that of WT-ABCG5 and -ABCG8,
respectively, suggesting that glycosylation defects in human ABCG5
and ABCG8 result in lesser protein stability (Figure 1b,e; Supplemen-
tary Figure S4).
Co- and post-translational N-glycosylation in human ABCG5 and
ABCG8. Most of N-glycosylation occurs co-translationally and is
mediated by STT3A, a catalytic subunit of OST complex in
mammalian cells, while rare examples of post-translational N-
glycosylation mediated by STT3B-containing OST complex in
mammalian cells have been reported5. We first examined which
OST catalytic subunit is involved in the N-glycosylation of the
ABCG5 and ABCG8 using STT3 isoform-specific siRNA. Immuno-
blotting showed that HM form of ABCG5 was decreased in cells with
STT3A knockdown, while STT3B knockdown slightly decreased HM
form but slightly increased Non-G form of ABCG5 (Figure 2a,c).
These data suggest contribution of both STT3A and STT3B in the
regulation of HM ABCG5 expression. On the other hand, HM form
of ABCG8 almost disappeared but Non-G form of ABCG8 was
accumulated when cells were transfected with siRNA targeting
STT3B but not STT3A (Figure 2b,c). Although there is a little
concern about si-STT3B specificity, the data suggest a dominant
contribution of STT3B in the regulation of HM ABCG8
glycosylation. Thus, these data demonstrate that STT3A- and
STT3B-containing OST complex are differentially involved in the
regulation of HM ABCG5 and ABCG8 expression and glycosylation.
Next, we determined how N-glycosylation occurs in ABCG5 and
ABCG8-expressing cells by pulse-label and -chase experiments. As
shown in Figure 2d, three bands that correspond to non-glycosylated
(Non-G), mono-glycosylated (Mono-G) and di-glycosylated (Di-G,
or HM) forms of ABCG5 proteins were observed after 15 to 30 mins
pulse-labeling. Similarly, two bands that correspond to Non-G and
Mono-G forms of ABCG8 protein were observed after longer pulse-
labeling (Figure 2d). Importantly, HM forms of both ABCG5 and
ABCG8 were lower than we expected in a short pulse-labeling period
(5 min) (Figure 2d,e: HM, 13.5% within all ABCG5 bands and 23.8%
within all ABCG8 bands), suggesting that these proteins are origin-
ally produced as a Non-G or Mono-G forms, albeit at different
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Figure 1 | Determination of N-linked glycosylation sites in human ABCG5 and ABCG8. (a) Putative asparagine residues to be N-glycosylated in human
ABCG5 protein. (b) Steady-state expression of monomeric Myc-tagged WT-, N584Q-, N591Q- and N584Q-/N591Q-ABCG5 was analyzed by
immunoblotting. (c) Endo H (500 U) and PNGase F (500 U) sensitivity of Myc-tagged WT-, N584Q-, N591Q- and N584Q-/N591Q-ABCG5 proteins
shown in (b). (d) Putative asparagine residue to be N-glycosylated in human ABCG8 protein. (e) Endo H and PNGase F sensitivity of HA-tagged WT- or
N619Q-ABCG8 proteins. (f) Schematic flow of intracellular trafficking pathway of ABCG5 and ABCG8 proteins. Complex-glycosylated, high-mannose,
di-glycosylated, mono-glycosylated and non-glycosylated forms of ABCG5 and ABCG8 proteins are represented as C-G, HM, Di-G, Mono-G and Non-G,
respectively. Gels have been cropped for clarity; full-length gels of Figure 1b, 1c and 1e are presented in Supplementary Figure S4.
www.nature.com/scientificreports
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Figure 2 | Co- and post-transcriptional N-glycosylation in human ABCG5 and ABCG8. (a), (b) STT3 siRNAs (100 nM)-transfected HEK293 cells were
co-transfected with Myc-ABCG5 (a) or HA-ABCG8 (b). Cell lysates were analyzed by immunoblotting. (c) Knockdown efficiencies of STT3A and STT3B
genes were analyzed by quantitative RT-PCR (Q-RT-PCR). Human 18s ribosmal RNA (18srRNA) was used as an internal control. *p , 0.05,
***p , 0.001, versus con siRNA-transfected cells; Dunnett’s test (n 5 3). (d), (e) Myc-ABCG5 or HA-ABCG8-transfected HEK293 cells were pulse
labeled for indicated time (5, 15, 30 min) and cell lysates were harvested immediately and digested with or without EndoH. Samples were
immunoprecipitated with anti-Myc or anti-HA antibody, followed by autoradiography (d). Relative quantity of each glycosylated form of ABCG5 or
ABCG8 within all ABCG5 or ABCG8 bands in a short pulse-labeling period (5 min) was quantified (e). (f–i) Pulse chase (pulse labeled for 10 min) of
HEK293 cells expressing Myc-tagged WT-, N584Q- and N591Q-ABCG5 (f). Relative quantity of each glycosylated form of WT-ABCG5 (g), N591Q-
ABCG5 (h) and N584Q-ABCG5 (i) within all ABCG5 was quantified. (j), (k) Pulse chase of HEK293 cells expressing HA-tagged WT-ABCG8 (j) and
relative quantity of each glycosylated form of WT-ABCG8 within all ABCG8 (k). Gels have been cropped for clarity; the bands were confirmed by the
comparison with full-length gel images (Supplementary Figure S4) and molecular weight.
www.nature.com/scientificreports
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degrees. The relatively higher expression levels of de-glycosylated
forms of ABCG5 and ABCG8 proteins in the early synthesized pro-
teins implies the involvement of post-translational glycosylation in
the regulation of these proteins. Consistently, pulse-chase analysis
using WT-ABCG5 and WT-ABCG8 revealed that the expression
level of glycosylated forms of WT-ABCG5 (Di-G and Mono-G)
and WT-ABCG8 (Mono-G) are gradually increased during the chase
period (Figure 2f,g: 21.8% 1 35.8% 5 57.6% to 68.6% 1 18.9% 5
87.5% for WT-ABCG5; Figure 2j,k: 23.9% to 55.0% for WT-ABCG8).
Based on the observed strong dependence of ABCG8 glycosylation
on STT3B (Figure 2b), the robust expression of Non-G form of
ABCG8 in the early synthesized protein (Figure 2d,e), and the
time-dependent increase of HM form of ABCG8 (Figure 2j,k), these
results suggest that ABCG8 is mainly post-translationally glycosy-
lated possibly via an STT3B-dependent mechanism.
To further characterize the glycosylation timing of each Asn resi-
dues (N584 and N591) of ABCG5 protein, mutational analysis using
N584Q- and N591Q-ABCG5 constructs were performed. Notably,
Non-G forms of both N584Q and N591Q ABCG5 proteins were
abundantly expressed (Figure 2f,h,i: 70.1% vs. 54.6%), indicating that
both Asn residues (N584 and N591) have the potential to be post-
translationally glycosylated although the tendency seems to be dif-
ferent among residues. Consistently, pulse-chase analysis using
N584Q and N591Q ABCG5 revealed that the expression level of
glycosylated forms of N584Q and N591Q ABCG5 are gradually
increased during the chase period (Figure 2f,h,i: 45.4% to 72.6%
for N584Q-ABCG5; 29.9% to 71.9% for N591Q-ABCG5). Because
of the high expression of Non-G form of N591Q ABCG5 at 0-min
chase (Figure 2f,h 70.1%) and of the time-dependent increase of
Mono-G form of ABCG5 (Figure 2f,h), we can deduce that most of
the N584 residue of ABCG5 is post-translationally glycosylated,
while N591 residue is both co- and post-translationally glycosylated.
The contribution of post-translational glycosylation in the ABCG5
regulation is consistent with the partial involvement of STT3B in the
regulation of ABCG5 glycosylation state, which was proven by the
experiment that shows a faint Non-G ABCG5 band after si-STT3B
introduction (Figure 2a). Overall, the data suggest that there is a
mixture of co- and post-translational mechanisms in the regulation
of N-glycosylation of HM forms of ABCG5 and ABCG8 proteins
although HM ABCG8 protein is mainly subjected to post-trans-
lational N-glycosylation in an STT3B-dependent manner, while
HM ABCG5 N-glycosylation seems to depend on both co- and
post-translational mechanisms.
Screening of E3 ubiquitin ligases that modulate expression pattern
of WT human ABCG5 or ABCG8. Despite the identification of the
sites for N-glycosylation in human ABCG5 and ABCG8 proteins
(Figure 1), the factors that regulate the N-glycosylation, are still
unknown. Because of the fact that monomeric human ABCG5 and
ABCG8 are retained in the ER as HM forms, and that proteasome is
likely a major pathway for degradation of HM forms of ABCG5 and
ABCG8 in ER2 (Supplementary Figure S5a–d), we attempted to
screen ER-associated E3 ubiquitin ligases to identify the molecules
involved in the regulation of expression and N-glycosylation of WT
human ABCG5 or ABCG8 in ER. Screening was performed by the
change of protein expression levels and patterns of HM ABCG5 and
HM ABCG8 bands after the overexpression of ER-associated E3
ubiquitin ligases (WT GP78, WT RMA1, WT HRD1 and WT
CHIP) that are previously shown to be involved in the degradation
of several ABC transporters16–18. We also tried the overexpression of
E3 activity-deficient dominant-negative mutant form of these E3
ligases (GP78 R2M, RMA1 C42S, HRD1 C329S and CHIP H260Q)
in this study. Overexpression of WT or dominant negative GP78 or
CHIP had little or no impact on steady state of HM forms of ABCG5
and ABCG8 (Supplementary Figure S5e,f, GP78 and CHIP). In
contrast, WT RMA1, but not C42S RMA1, overexpression
decreased the expression level of HM forms of ABCG5 and
ABCG8 (Supplementary Figure S5e,f, RMA1), suggesting that
RMA1 accelerates the degradation of both ABCG5 and ABCG8 in
an E3 activity-dependent manner. Although there seems to be two
bands that correspond to HM and lower molecular weight (LMW)
({) of ABCG8 proteins in pcDNA3.1-transfected condition
(Supplementary Figure S5f, pcDNA3.1), only LMW band is
observed in WT RMA1-, but not C42S RMA1-transfected lanes,
and these LMW bands were not altered among the samples
(Supplementary Figure S5f, WT and C42S RMA1), suggesting that
RMA1 specifically accelerates the degradation of HM ABCG8 band
in an E3-dependent manner. On the other hand, although WT HRD1
did not affect HM form of ABCG5, C329S HRD1 strongly induced its
accumulation (Supplementary Figure S5f, HRD1), implicating that
HRD1 may also accelerate the degradation of ABCG5 in an E3
activity-dependent manner. Notably, both WT HRD1 and C329S
HRD1 overexpression decreased the band of HM ABCG8 and
increased the band of LMW of ABCG8 (#) (Supplementary Figure
S5f, HRD1). Similarly, both WT HRD1 and C329S HRD1
overexpression slightly increased the bands of LMW of ABCG5 ({)
(Supplementary Figure S5e, HRD1). Taken together, although the
effect of HRD1 on the regulation of HM ABCG8 protein and the
characteristics of LMW bands of ABCG5 ({) and ABCG8 ({, #) are
yet unclear, the data indicate that RMA1 and HRD1 are the critical
molecules that control the expression of both ABCG5 and ABCG8
proteins.
HRD1 accumulates non-glycosylated human ABCG8. We next
sought to determine the nature LMW band (#) that was signi-
ficantly observed when cells were co-transfected with ABCG8 and
WT or C329S HRD1. We further confirmed the increased expression
of LMW band by the dose-dependent transfection with WT HRD1
(Figure 3a, lanes 1–4). Because the decrease in molecular weight was
2–3 kDa and human ABCG8 possesses one site for N-glycosylation
(Figure 1d,e), we hypothesized that the LMW band (#) is Non-G
form of human ABCG8. As expected, HRD1-induced LMW of
human ABCG8 was similar in size to Endo H- or PNGase F-
treated human ABCG8 (Non-G) (Figure 3b, lanes 2–4). Moreover,
Endo H or PNGase F had no impact on the size of HRD1-induced
LMW band (Figure 3b, lanes 4–6), indicating that HRD1-induced
LMW band was indeed the Non-G form of human ABCG8. Notably,
effect of dominant-negative mutant form of HRD1 (C329S HRD1)
was identical to that of WT form (Figure 3a, lanes 1, 5–7), suggesting
that HRD1-induced LMW band appearance does not require its E3
activity. This was also confirmed by another dominant-negative
mutant form of HRD1 (C291S/C329S HRD1) (Figure 3c). In these
conditions, ABCG8 protein can interact with WT HRD1 (Figure 3d),
suggesting that HRD1 overexpression decreases N-glycosylated
human ABCG8 and accumulates non-glycosylated ABCG8
possibly through their interaction.
HRD1 inhibits STT3B-dependent posttranslational N-glycosyla-
tion of human ABCG8. We further investigated whether HRD1-
induced accumulation of Non-G form of human ABCG8 was due to
the inhibition of N-glycosylation by HRD1. Because, as shown in
Figure 2, most of ABCG8 protein is likely post-translationally N-
glycosylated by STT3B, we next sought to understand the possible
involvement of HRD1 on the regulation of posttranslational N-
glycosylation. Pulse chase analysis after HRD1 transfection was
performed and showed that when pulse labeled for 10 min, a tiny
HM band can be observed (Figure 3e, lane 1, 25%) and this band is
diminished by WT HRD1 expression (Figure 3e, lane 2, 12%).
Moreover, despite the noticeable conversion from Non-G to HM
form during 2 hrs chase period (Figure 3f, lanes 1–4, from 27 to
53%), conversion was inhibited in both WT and C329S HRD1-
transfected conditions (Figure 3f, lanes 5–8, from 15 to 17%; lanes
9–12, from 13 to 19%). Finally, co-immunoprecipitation assay
www.nature.com/scientificreports
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Figure 3 | HRD1 accumulates non-glycosylated human ABCG8 by inhibiting STT3B-dependent post-translational N-glycosylation. (a–c) Cell lysates
from HA-ABCG8-expressing HEK293 cells transfected with empty vector or serial amounts of expression vectors that encode Myc-tagged WT or C329S
HRD1 (a), (c) or C291S/C329S HRD1 (c) were analyzed by immunoblotting. # indicates the band of LMW. Cell lysates from WT HRD1-transfected
HEK293 cells were digested with EndoH or PNGase F, and analyzed by immunoblotting (b). (d) HEK293 cells were transiently co-transfected with HA-
ABCG8 and Myc-HRD1. ABCG8 protein was immunoprecipitated by using anti-HA antibody or non-immunized IgG (control IgG) and
immunoprecipitants were analyzed by Western blotting (upper panels). Input protein, cell lystes without immunoprecipitation of antibodies, was used as
a positive control (lower panels). (e) HA-tagged ABCG8-expressing HEK293 cells were transfected with WT-HRD-1, and pulse labeled for 10 min. Cell
lysates were harvested immediately and were digested with or without EndoH, and immunoprecipitated with anti-HA antibody, followed by
autoradiography. HM ratio (%) was calculated based on the band intensities of HM and Non-G ABCG8 proteins [HM/(HM 1 Non-G)]. (f) Pulse chase
analysis of HA-ABCG8-expressing HEK293 cells transfected with empty vector, Myc-tagged WT HRD-1 or C329S HRD1. After the indicated chase
period, cell lysates were immunoprecipitated with anti-Myc antibody, followed by analysis with autoradiography. HM ratio (%) was calculated as
explained in (e). (g) Samples in (d) were digested with or without EndoH and immunoprecipitated with HRD1 protein using anti-Myc antibody or
control IgG and immunoprecipitants were analyzed by Western blotting. Input protein (cell lystes without immunoprecipitation of antibodies) was used
as positive control. Gels have been cropped for clarity; the bands were confirmed by the comparison with full-length gel images (Supplementary Figure
S4) and molecular weight.
www.nature.com/scientificreports
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revealed that non-glycosylated, but not glycosylated, human ABCG8
interacted with WT HRD1 (Figure 3g), suggesting that HRD1 inhibits
posttranslational N-glycosylation of human ABCG8 possibly by
interacting with ABCG8 protein before sugar chains are added by
STT3B-containing OST complex.
Characterization of HRD1 regions responsible for the accumu-
lation of non-glycosylated human ABCG8. To investigate which
HRD1 region inhibits N-glycosylation of human ABCG8, a series of
HRD1 mutants was prepared (Figure 4a). HEK 293 cells were
transiently transfected with human ABCG8 along with WT HRD1,
membrane (M) HRD1 or membrane-RING (MR) HRD1. WT and
MR but not M HRD1 induced accumulation of Non-G form of
human ABCG8 (Figure 4b). Importantly, immunoprecipitation
analysis further revealed a strong interaction between WT HRD1
and Non-G ABCG8 proteins (Figure 4d). Notably, there is also an
interaction between MR HRD1, but not M HRD1, and Non-G
ABCG8 proteins (Figure 4c,d). Moreover, MR HRD1, but not
M HRD1, induced Non-G ABCG8 expression (Figure 4b,d).
Since the levels of induction of Non-G ABCG8 expression and
of interaction with Non-G ABCG8 are positively correlated
(Figure 4d), HRD1-dependent Non-G ABCG8 induction depends
on the strength of their interaction. Because of the facts that both
WT and MR HRD1 proteins possess RING domain and proline-rich
domain is not included in MR HRD1, RING finger domain of HRD1
is likely a critical region in both its interaction with Non-G ABCG8
and its induction of Non-G ABCG8 expression, while proline-rich
domain of HRD1 may partially contribute to its binding to Non-G
ABCG8 protein that increases induction of Non-G ABCG8
expression.
Figure 4 | RING finger domain is critical for HRD1-induced accumulation of non-glycosylated human ABCG8. (a) Schematic representation of the
HRD1 constructs. The panel diagrammatically represents WT-HRD1 and a variety of deletion mutants-HRD1 (M- and MR-HRD1). Numbers in
parentheses indicate the corresponding amino acid residues of HRD1. (b) HEK293 cells were co-transfected with HA-ABCG8 and WT-, M- or MR-
HRD1. Cell lysates were recovered 48 hr after transfection, followed by immunoblotting. HSC70 was used as internal control. (c) HEK293 cells were co-
transfected with HA-ABCG8 plasmid and expression vectors that encode Myc-tagged WT-, M- or MR-HRD1. HRD1 protein was immunoprecipitated
by using anti-Myc antibody or control IgG, and immunoprecipitants were analyzed by immunoblotting. Input protein was used as positive control. (d)
Summary of the effects of WT-, M- and MR-HRD1 on the induction of non-G ABCG8 expression based on the analysis as shown in (b), (c). A tick
indicates the presence of the domains whereas a cross indicates the absence of the domains in each protein structure. The levels of Non-G ABCG8
induction and the strength of interaction with Non-G ABCG8 were indicated as a different number of plus signs (1) in each column. Gels have been
cropped for clarity; the bands were confirmed by the comparison with full-length gel images (Supplementary Figure S4) and molecular weight.
www.nature.com/scientificreports
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ABCG8 N-glycosylation is critical for its protein stability and
HRD1 accelerates ABCG8 degradation by diminishing ABCG8
N-glycosylation. As shown in Figure 1e, because the steady state
expression of N-glycosylation defective mutant of human ABCG8
was lower when compared to that of WT-ABCG8, we sought to
evaluate the protein stability of human N619Q ABCG8 in detail.
As shown in Figure 5a and 5b, protein stability of N619Q ABCG8
was clearly lower than that of WT ABCG8. Steady state expression of
N619Q further indicated lower protein stability of human N619Q
ABCG8 (Figure 5c). To determine whether the stability of WT
HRD1-induced Non-G form of ABCG8 is also decreased, we
transfected HEK293 cells with 1 mg of HRD1 construct, which
resulted in the appearance of both Non-G and HM forms of
ABCG8, and CHX chase experiments were performed. Impor-
tantly, protein stability of Non-G form of ABCG8 derived from
HRD1 transfection was also lower than that of HM form of
ABCG8 (Figure 5d and 5e). Percentage of remaining Non-G form
derived from HRD1-transfected ABCG8 protein at 2 and 4 hrs was
almost identical to that of N619Q ABCG8 (Figure 5b,e, 44.40% vs.
43.95% at 2 hrs; 26.01% vs. 29.36% at 4 hrs). Moreover, the
percentage of remaining HM form at 2 and 4 hrs was also
identical to that of WT ABCG8 (Figure 5b and 5e, 82.72% vs.
84.68% at 2 hrs; 64.03% vs 70.68% at 4 hrs). These data suggest
that HRD1 does not directly affect protein stabilities of Non-G and
HM forms of ABCG8 proteins per se. Consistently, HRD1 does not
further affect protein stability of Non-G N619Q ABCG8 protein
(Figure 5f,g).
Having demonstrated that WT and C329S HRD1 induce the accu-
mulation of Non-G ABCG8 protein that has a lower stability than
HM ABCG8 protein, these HRD1 proteins may accelerate ABCG8
degradation by increasing Non-G form of ABCG8 protein. We trans-
fected HEK293 cells with 2 mg of HRD1 constructs, which resulted in
the appearance of only Non-G form of ABCG8, and CHX chase
experiments were performed (Figure 5h). The cell lysates were fur-
ther digested with Endo H to precisely quantify total amount of
ABCG8 protein (Figure 5i,j). As we expected, similar decreased pro-
tein stabilities of Non-G forms derived from WT HRD1- and C329S
HRD1-coexpressed ABCG8 were observed (Figure 5h–j), indicating
that HRD1 certainly decreases total ABCG8 protein stability in the
E3 activity-independent manner. To reveal that endogenous HRD1
also affects ABCG8 protein expression, we decrease HRD1 express-
ion by siRNA technique. Importantly, knockdown of HRD1
increases the steady state expression of ABCG8 protein
(Figure 5k), suggesting that endogenous HRD1 suppresses ABCG8
protein expression. However, si-HRD1-dependent stabilization of
HM-ABCG8 protein per se was relatively slight (Figure 5l, m). In
this condition, ABCG8 protein interacts with endogenous HRD1
(Figure 5n). Due to an undetectable base line expression of Non-G
ABCG8 protein in our analysis, the si-HRD1 experiment could not
directly demonstrate that endogenous, in addition to exogenous,
HRD1 proteins inhibit N-glycosylation of HM ABCG8. Overall,
our data support the idea that ABCG8 N-glycosylation is critical
for its protein stability and HRD1 lessens ABCG8 expression, con-
ceivably by diminishing ABCG8 N-glycosylation.
RMA1 facilitates ERAD of HM forms of human ABCG5 and
ABCG8 proteins. Having suggested that WT RMA1 overexpression
strongly decreases both HM forms of human ABCG5 and ABCG8
proteins (Supplementary Figure S5e,f), we further determined the
relationship between RMA1 and HM form of ABCG5 or ABCG8.
Similar to Supplementary Figure S5, steady states of HM forms of
human ABCG5 and ABCG8 proteins were reduced by WT RMA1
overexpression, but not by C42S RMA1 (Figure 6a,b). Consistently,
CHX chase analysis further confirmed that only WT RMA1
accelerates degradation of HM form of ABCG5 and ABCG8 pro-
teins, while C42S RMA1 does not seem to induce degradation
(Figure 6c–f). In these conditions, HM forms of ABCG5 and
ABCG8 proteins interact with WT RMA1 as well as C42S RMA1
(Supplementary Figure S6a,b). These data clarify that RMA1
suppresses the expression of both monomeric human ABCG5 and
ABCG8 proteins probably through its E3 activity.
HRD1 mainly facilitates ERAD of HM forms of human ABCG5
proteins. We also confirmed the effect of HRD1 on HM form of
ABCG5. Similar to Supplementary Figure S5, WT HRD1 did not
affect HM form of ABCG5, while C329S HRD1 strongly induced
its accumulation (Figure 6g). Consistently, CHX chase analysis
also revealed that C329S HRD1 strongly attenuates protein
degradation of HM form of ABCG5 protein during chase period
(Figure 6h,i). In these conditions, HM form of ABCG5 protein
interacts with WT HRD1 as well as C329S HRD1 (Supplementary
Figure S6c). On the other hand, although both WT HRD1 and C329S
HRD1 overexpression slightly increased the band of LMW of
ABCG5, which is considered as the Non-G ABCG5 protein
(Figure 6g, Non-G; Supplementary Figure S7, lanes 4–6, Non-G) as
it is also observed in Supplementary Figure S5e ({), induction of
Non-G ABCG5 was much less than that observed in the case of
Non-G ABCG8 protein. Overall, these data demonstrate that
RMA1 accelerate the degradation of both ABCG5 and ABCG8
proteins, and HRD1 seems to mainly accelerate the degradation of
ABCG5 protein, in an E3 activity-dependent manner (Figure 7e).
The effect of RMA1 or HRD1 on maturation of ABCG5/G8
complex. Finally, to determine the role of RMA1 and HRD1 in the
regulation of plasma membrane expression of ABCG5/ABCG8
complex, we transfected the cells with both ABCG5 and ABCG8
constructs together with WT or E3 defective mutants of RMA1 or
HRD1. As determined in Figure S1A and S1B, C-G forms of ABCG5
and ABCG8 after various combination of transfection were
quantified by immunoblot gel images. Consistent with the effect of
WT and C42S RMA1 on monomeric expression of ABCG5 and
ABCG8, only WT but not C42S RMA1 reduced the expression of
C-G forms of ABCG5 and ABCG8 (Figure 7a,b), suggesting E3
activity-dependent negative regulatory role of RMA1 in the
posttranslational regulation of ABCG5/ABCG8 complex. On the
other hand, both WT and C329S HRD1 reduced expression of C-
G forms of ABCG5 and ABCG8 to an almost similar pattern and
extent (Figure 7c,d), indicating E3 activity-independent negative
regulatory role of HRD1 in the posttranslational regulation of
ABCG5/ABCG8 complex.
Discussion
N-glycosylation is one of the important post-translational modifica-
tions that occur in the ER2. Our study focuses on identification of
mechanisms responsible for N-glycosylation of ABCG5/8 transpor-
ters, and of factors involved in its regulation. Based on our results, the
following model is proposed for N-glycosylation-associated quality
control of ABCG5 and ABCG8 proteins by the E3 ligase proteins in
the ER (Figure 7e). Among two E3 ligase proteins determined by
overexpression-based screening, RMA1 is likely a factor that accel-
erates the degradation of both ABCG5 and ABCG8 proteins in an E3
activity-dependent manner. HRD1, another E3 ligase protein, also
mainly accelerates the degradation of ABCG5 protein probably
through E3 activity-dependent mechanism. Having demonstrated
that RMA1 and HRD1 are well-established E3 ubiquitin ligases
and their RING finger domains exert suppressive effects through
their capability to induce ERAD16,17, it is highly likely that the effects
are E3 activity-dependent although direct ubiquitin addition was not
monitored in the present study. In contrast, HRD1 does not directly
accelerate the degradation of ABCG8 protein, but rather accelerates
its degradation through an indirect mechanism, that is, diminished
STT3B-dependent post-translational N-glycosylation of ABCG8,
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Figure 5 | HRD1 accelerates ABCG8 degradation by reducing its protein stability through the inhibition of ABCG8 N-glycosylation. (a), (b) Stability of
WT- or N619Q-ABCG8 in HEK293 cells was determined by CHX (50 mM) chase experiment (a). HM or Non-G forms of ABCG8 were quantified and
normalized by HSC70 expression. Data are presented as the percentage of the amount detected at 0 hr (b). **p , 0.01, ***p , 0.001, versus WT ABCG8-
transfected cells; Student’s t test (n 5 3). (c) Steady-state expression of HEK293 cells transfected with WT- or N619Q-ABCG8. Cell lysates were subjected
to immunoblotting (upper panel). Relative expression of Non-G form of ABCG8 were calculated (n 5 3) (lower panel). (d), (e) Stabilities of HM and
Non-G forms of WT-ABCG8 protein derived from Myc-HRD1 (1 mg)-transfected HEK293 cells were determined by CHX chase experiment (d). HM or
Non-G forms of WT-ABCG8 were quantified (e). *p , 0.05, **p , 0.01, versus HM ABCG8 bands; Student’s t test (n 5 3). (f), (g) Stability of Non-G
N619Q-ABCG8 protein in HEK293 cells transfected with Myc-HRD1 (f). Non-G N619Q-ABCG8 protein was quantified (n 5 3) (g). (h–j) WT-ABCG8
and Myc-tagged WT- or C329S-HRD1 were co-transfected and cells are subjected to CHX chase experiment. After recovery, cell lysates were digested with
(i) or without (h) EndoH, and were analyzed by immunoblotting. Stability of total ABCG8 protein after transfection with HRD1 constructs was
quantified using Endo H (1) shown in (i) and normalized by HSC70 expression (j). *p , 0.05, **p , 0.01, #p , 0.05, versus pcDNA6-transfected cells;
Student’s t test (n 5 3). Student’s t test (n 5 3). (k) Steady-state expression of HEK293 cells transfected with si-GL2 (control si-RNA) or si-HRD1. Cell
lysates were subjected to immunoblotting (upper panel). Relative expression of HM ABCG8 was calculated (n 5 3) (lower panel). (l), (m) Stabilities of
HM form of WT-ABCG8 protein derived from si-GL2 or si-HRD1-transfected HEK293 cells (l). HM form of WT-ABCG8 was quantified (m) (n 5 6 for
si-GL2, n 5 3 for si-HRD1). (n) ABCG8 protein transfected in HEK293 cells was immunoprecipitated and immunoprecipitants were analyzed by
Western blotting (IB). Input protein, cell lystes without immunoprecipitation of antibodies, was used as a positive control (input). Gels have been
cropped for clarity; the bands were confirmed by the comparison with full-length gel images (Supplementary Figure S4) and molecular weight.
www.nature.com/scientificreports
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Figure 6 | RMA1 and/or HRD1 facilitates ERAD of HM forms of human ABCG5 and/or ABCG8 proteins. (a), (b) Steady-state expression of ABCG5
(a) and ABCG8 (b) proteins in HEK293 cells transfected with empty vector or serial amounts of expression vectors that encode Flag-tagged WT or C42S
RMA1 were analyzed by immunoblotting. (c–f) Stability of ABCG5 (c) or ABCG8 (d) proteins in HEK293 cells transfected with empty vector, WT or
C42S RMA1 was determined by CHX (50 mM) chase experiments. HM forms of ABCG5 (e) or ABCG8 (f) were quantified and normalized by HSC70
expression. Data are presented as the percentage of the amount detected at 0 hr. **p , 0.01, versus pcDNA3.1-transfected cells; Student’s t test (n 5 3–6).
(g) Steady-state expression of ABCG5 protein in HEK293 cells transfected with empty vector or serial amounts of expression vectors that encode WT or
C329S HRD1 were analyzed by immunoblotting. (h), (i) Stability of ABCG5 protein in HEK293 cells transfected with empty vector, WT or C329S HRD1
was determined by CHX (50 mM) chase experiments (h). HM form of ABCG5 was quantified and normalized by HSC70 expression. Data are presented as
the percentage of the amount detected at 0 hr (i). **p , 0.01, versus pcDNA6-transfected cells; Student’s t test (n 5 6). (j) Schematic flow of E3 activity-
dependent posttranslational regulation of ABCG5 and ABCG8 by RMA1 and HRD1. RMA1 accelerates the degradation of both ABCG5 and ABCG8
proteins, and HRD1 also seems to accelerate the degradation of ABCG5 protein, in an E3 activity-dependent manner. Gels have been cropped for clarity;
the bands were confirmed by the comparison with full-length gel images (Supplementary Figure S4) and molecular weight.
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Figure 7 | RMA1 and HRD1 are negative regulators of ABCG5/G8 maturation. (a–d) Steady-state expression of C-G forms of ABCG5 and ABCG8
proteins in HEK293 cells transfected with empty vector or serial amounts of expression vectors that encode Flag-tagged WT or C42S RMA1 (a) and Myc-
tagged WT or C329S HRD1 (c) was analyzed by immunoblotting. * indicates non-specific band. Mature C-G forms of ABCG5 and ABCG8 protein bands
after transfection with RMA1 (b) and HRD1 (d) constructs were calculated and data are presented as the percentage of the amount detected in empty
vectors-transfected control. *p , 0.05, **p , 0.01, ***p , 0.001, versus empty vector-transfected cells; Dunnett’s test (n 5 3). Gels have been cropped
for clarity; the bands were confirmed by the comparison with full-length gel images (Supplementary Figure S2 and S3) and molecular weight. (e)
Schematic flow of RMA1- and HRD1-dependent post-translational regulation of ABCG5 and ABCG8 proteins. RMA1 accelerates the degradation of both
ABCG5 and ABCG8 proteins, and HRD1 mainly accelerates the degradation of ABCG5 protein, in an E3 activity-dependent manner, while HRD1
accelerates ABCG8 degradation by diminishing the STT3B-dependent post-translational N-glycosylation of ABCG8 in an E3 activity-independent
manner. Since ABCG5 N-glycosylation is also mediated by post-translational mechanism (mainly at N584 and partially at N591), HRD1 may inhibit
ABCG5 N-glycosylation although the possibility seems to be minor based on the data. Hence, both RMA1 and HRD1 are negative regulators of ABCG5/
ABCG8 maturation.
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which lessens the stability of ABCG8 protein. This process may be
designated as ‘‘E3-independent degradation’’ (Figure 7e) because of
the fact that E3 activity-defective mutant of HRD1 (C329S and
C329S/C291S) could also increase Non-G form of ABCG8
(Figure 3a,c). On the other hand, HRD1 has only slight effect on
the N-glycosylation of ABCG5, although post-translational mech-
anism is also involved in the N-glycosylation at Asn 584 of ABCG5,
and partly involved at Asn 591 of ABCG5. Given the facts that (1)
RING domain-containing MR HRD1, but not RING domain-miss-
ing M HRD1, could bind to ABCG8 and induce Non-G form of
ABCG8 (Figure 4), (2) interaction of HRD1 with ABCG8 protein
was limited to its Non-G form (Figure 3h), and (3) the conversion
from Non-G to HM forms of ABCG8 was inhibited in both WT and
C329S HRD1-transfected conditions (Figure 3f), HRD1 exerts its
inhibitory action probably through its RING finger domain. This is
the first report to show that RING-finger domain in E3 ubiquitin
ligases contributes to protein-protein interaction without directly
affecting the proteasomal degradation pathway, which leads to
diminished N-glycosylation of substrate by STT3B. Overall, it is quite
possible that HRD1 masks the N-glycosylation site of ABCG8 to
protect from STT3B-dependent glycosylation.
One of the key findings in this study is that both ABCG5 and
ABCG8 are post-translationally N-glycosylated. Our mutational
metabolic labeling analysis further suggested that ABCG8 is post-
translationally N-glycosylated at N619 in an STT3B-dependent
manner, while ABCG5 is N-glycosylated depending on both co-
and post-translational mechanisms at N584 and N594 although
N584 tends to be more post-translationally glycosylated based on
the pulse-chase analysis (Figure 2f,h,i). What determines the timing
of glycosylation, co- or post-translational modification, and STT3s’
enzymatic specificities? Importantly, C-terminal Asn-X-Thr sites,
but not Asn-X-Ser sites, located at ,50 residues (boundary is located
between 50 and 55 residues from the C terminus of a protein) appear
to be preferably post-translationally N-glycosylated more efficiently
by STT3B in other substrate proteins19. Notably, sequons locate at
54–67 residues of ABCG5 and ABCG8 proteins, implying that those
sites have a potential to be post-translationally N-glycosylated. In
fact, the expression analysis of Non-G forms of Asn-mutated ABCG5
and WT-ABCG8 proteins during pulse period indicated that all Asn
sites (N584 and N591 of ABCG5 and N619 of ABCG8) are post-
translationally N-glycosylated, albeit at different levels (N619 of
ABCG8 $ N584 of ABCG5 . N591 of ABCG5). Consistently, the
sequons of the highly probable sites, N619 of ABCG8 and N584 of
ABCG5, are Asn-Leu-Thr and Asn-Phe-Thr, respectively, both of
which fits the above-mentioned rule of post-translational N-glyco-
sylation in terms of amino acid sequences (Asn-X-Thr rule)
(Supplementary Figure S8). Together, these data are consistent with
the finding that shows relationship between sequon and timing of
glycosylation (co- or post-translational) shown by Shrimal et al.19. To
make sure this rule can be also applied for other ABCG subfamily
members, we performed sequon analysis in other ABCG family pro-
teins. As shown in Supplementary Figure S5, in addition to ABCG5
and ABCG8, sequon of ABCG2 (BCRP) protein around position 596
is Asn-Ala-Thr and sequon locates at 59 residue of ABCG2 protein,
implicating that ABCG2 could be also post-translationally N-glyco-
sylated. Despite an absence of direct evidence that supports this
hypothesis, our previous study showed that overexpression of
HRD1, which is shown to strongly inhibit post-translational N-gly-
cosylation of ABCG8 in the present study, also slightly increases
Non-G form of ABCG2 (Figure 1D in the report)20, supporting the
idea that the N-glycosylation of ABCG2 is mediated by post-trans-
lational mechanism in which STT3B and HRD1 may be involved.
Further pulse chase analysis would be needed to confirm this
hypothesis.
Despite the clear evidence of the contribution of STT3B to the
post-translational N-glycosylation of ABCG8 based on the
si-STT3B analysis (Figure 2b), which STT3 isoform contributes to
the post-translational N-glycosylation of ABCG5 could not be clearly
identified in the present study. Since STT3B knockdown slightly
accumulates Non-G ABCG5 band (Figure 2a), it is quite obvious
that there is some contribution of STT3B-dependent post-trans-
lational mechanism in the regulation of ABCG5 N-glycosylation,
which is consistent with the conclusion obtained from the data of
pulse-chase analysis (Figure 2 f,g,h,i). On the other hand, N591 of
ABCG5 seems to be in part co-translationally N-glycosylated
because half of ABCG5 is originally produced as a Mono-G form
(Figure 2f,i, 0 hr, Mono-G, 45.4%). However, STT3A knockdown
does not increase deglycosylated forms (Mono-G, Non-G) of
ABCG5 (Figure 2a). This may be due to possibilities that (1) basal
expression level but not N-glycosylation status of ABCG5 is directly
or indirectly regulated by STT3A, or (2) N-glycosylation of ABCG5 is
actually regulated by STT3A, however, the stability of si-STT3A-
induced non-G ABCG5 might be too low to visualize in the condition
we used in the study. Further analysis would be needed to access how
ABCG5 N-glycosylations at N584 and N591 sites are regulated, or
especially which isoforms of STT3 proteins are involved.
Another point to be considered is whether HRD1 also affects the
glycosylation of ABCG5 protein. At most, there is a very faint Non-G
ABCG5 band after HRD1 overexpression (Supplementary Figure
S7a, Figure 6g). Importantly, the faint Non-G ABCG5 band can be
also observed by si-STT3B introduction (Figure 2a). Moreover, both
WT- and C329S-HRD1 overexpression in the ABCG5/8 co-express-
ion model seems to slightly increase the Non-G ABCG5 band as well
as strongly increase the Non-G ABCG8 band (Figure 7c). These data
suggest that HRD1 also inhibits ABCG5 N-glycosylation via the
inhibition of STT3B-dependent N-glycosylation machinery
although the inhibitory effect seemed to be very low. The specific
action of HRD1 in the regulation of N-glycosylation of ABCG8, but
not of ABCG5, and the fact that no change in mRNA expression of
STT3A and STT3B was observed during HRD1 transfection con-
dition (Supplementary Figure S9), support the idea that HRD1 does
not regulate STT3B, but instead sequesters ABCG8.
In general, N-glycosylation of secretory or membrane glycopro-
teins in the ER has an important role in the ER quality control
(ERQC) system2. Consistently, hypoglycosylation causes defects in
glycoprotein folding, secretion, and function that sometimes con-
tribute to the pathophysiological symptoms21. Until now, most of
the research has focused on ‘‘glycosylation-dependent’’ ERQC sys-
tem and characterized dynamic ‘‘glycan code’’ theories2,5. Although
in previous studies mutational analysis of glycoproteins clearly
demonstrated that Non-G form of glycoproteins is generally suscept-
ible to ERAD9,10,20,22–24, factors that compel substrate glycoproteins to
be degraded in a ‘‘non-glycosylation (Non-G)-dependent’’ manner
have been unknown. The present study is first to show ABCG8 as one
of the proteins that could be subjected to ‘‘Non-G-dependent’’ ERAD
and to demonstrate that this is mediated by HRD1 E3 ubiquitin ligase
through the suppression of STT3B-dependent N-glycosylation,
regardless of its E3 ligase activity. Identification of the molecules that
are critical for the ‘‘Non-G-dependent’’ ERAD is essential to further
understand this unique ERQC system.
Overall, our data demonstrate that RMA1 and HRD1 are negative
regulators of ABCG5/ABCG8 transporter (Figure 7e). What is the
physiological relevance of RMA1- and HRD1-dependent ABCG5/8
regulation? Growing evidence supports the importance of expression
levels and function of RMA1 and HRD1 in the physiological and
pathophysiological conditions. RMA1 expression is associated with
autophagic25 and anti-viral responses26, and disease progression such
as degenerative myopathy27 and breast cancer28. On the other hand,
HRD1 has been shown to be up-regulated during ER stress to protect
the cells by eliminating misfolded proteins including mutant insulin
and amyloid precursor protein29,30. Because there are no reports
evaluating the correlation between the levels of RMA1 or HRD1
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and the incidence of lipids-related diseases which could be caused by
defects of ABCG5/8 transporter, epidemiological assessment may be
beneficial to help to clarify the physiological relevance of our
findings.
In summary, we have shown that both ABCG5 and ABCG8 pro-
teins are post-translationally N-glycosylated. Among theses, ABCG8
is a novel protein that is post-translationally N-glycosylated via
STT3B. Given the facts that the reports on STT3B-targeted substrate
proteins are quite limited and this becomes a first example within
multi-spanning membrane glycoproteins, our findings would pro-
vide new insights into fundamental mechanisms in the ERQC of
other ABC transporters and/or membrane proteins. Moreover,
among the results that showed suppression of ABCG5 and ABCG8
proteins by RMA1 and HRD1, the finding of E3 activity-independent
negative regulation of post-translational ABCG8 glycosylation by
HRD1 may open a gate to how Non-G-dependent ERAD pathway
is physiologically and pathophysiologically regulated. Although our
si-HRD1 approaches were only able to show the increase in the
steady state expression of HM ABCG8 (Figure 5k) and the increase
of mature forms of ABCG5 and ABCG8 proteins (Supplementary
Figure S10), but not able to directly prove the obvious change of
glycosylation state of ABCG8, due to an undetectable base line
expression of Non-G ABCG8 protein at the experimental condition,
our studies demonstrate a HRD1-dependent unique inhibitory
mechanism of ABCG8 post-translational N-glycosylation, which
results in a decreased ABCG8 protein expression, thereby suppres-
sing full maturation of ABCG5/8 transporter.
Methods
DNA constructs. Cloning of human ABCG5 and ABCG8 cDNA (accession numbers
NM022436 and NM022437, respectively) and introduction of Myc-tag and HA-tag
sequences into the constructs were as previously described31. Human Myc-ABCG5
cDNA and human HA-ABCG8 cDNA were subcloned into pTRE-Shuttle2 vector.
For the expression of ABCG5 and ABCG8, pTRE-Shuttle2 vectors containing Myc-
ABCG5 and HA-ABCG8 were co-transfected with pTet-off vector (Takara-Clontech,
Tokyo, Japan). Glycosylation-defective mutants N584Q-, N591Q-, N584Q/N591Q-
ABCG5, N619Q-ABCG8, and E3-defective mutants C291S/C329S-HRD1, H260Q
CHIP and C42S-RMA1 were generated using the QuikChange II site-directed
mutagenesis kit (Stratagene, La Jolla, CA) according to previous reports12,17,32–34.
Expression plasmids for WT CHIP and WT Rma1 were constructed as previously
described17. Expression plasmids for WT HRD1 and C329S HRD1 were constructed
as previously described32. Expression plasmids for WT GP78 and GP78 R2M were
kindly provided by Dr. Allan M Weissman (National Cancer Institute, NIH)35.
Reagents and antibodies. MG-132 was purchased from Calbiochem (San Diego,
CA). Cycloheximide (CHX), digitonin, protease inhibitor cocktail and chloroquine
were purchased from Sigma (St. Louis, MO). Endoglycosidase H (Endo H) and
Peptide:N-Glycosidase F (PNGase F) were purchased from New England Biolabs
(Ipswich, MA). Protein G Sepharose 4 Fast Flow was purchased from GE Healthcare
(Waukesha, WI). The following antibodies were used in this study: Anti-myc
monoclonal antibody (9E10), anti-HA probe monoclonal antibody (F7), anti-Rma1/
RNF5 monoclonal antibody and non-immunized control IgG (Santa Cruz
Biotechnology, Santa Cruz, CA), anti-myc polyclonal antibody (06-549; Upstate-
Millipore, Charlottesville, VA), anti-HSC70 (clone 1B5; SPA-815; Stressgen
Biotechnologies, Victoria, BC, Canada), anti-HRD1 (SYVN1; C-term; ABGENT, San
Diego, CA), anti-HA polyclonal antibody (ab9143; Abcam Inc., Cambridge, MA),
anti-ABCG8 polyclonal antibody (NB400-110; NOVUS Biologicals, Littleton, CO).
Cell culture, transfection of plasmid DNA and siRNA. HEK293 cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM, Wako) supplemented with 10%
fetal bovine serum (FBS). Cells were maintained at 37uC in a humidified atmosphere
of 5% CO2 and 95% air. Transient transfections of plasmid DNA were performed with
Hilymax (Dojin Co. Ltd, Tokyo, Japan) by following the manufacturer’s
recommendations. StealthTM RNAi targeting STT3A (HSS105598), STT3B
(HSS176509) and negative Universal Control were purchased from Invitrogen
(Carlsbad, CA). siRNAs targeting to human HRD1 (59- CGTTCCTGGTACGCCG-
TCATT-39) and GL2 luciferase (negative control) (59-CGUACGCGGAAUACUU-
CGATT-39) were synthesized and obtained from Sigma Genosys Aldrich (Japan). For
siRNA transfection, siSTT3A and siSTT3B (100 nM) were transiently transfected
into HEK293 by Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturer’s instructions. Stealth RNAi Low GC Duplex was used as a negative
control siRNA. To co-transfect siRNA and cDNA plasmids, plasmid transfection was
performed after 24 hr of siRNA transfection, and then cells were cultured for further
48 hr. The knockdown efficiency was confirmed by quantitative real-time RT-PCR
(Q-RT-PCR).
Cell lysis, SDS-PAGE, Immunoblotting. Cells were washed twice with ice-cold PBS
and lysed in RIPA Buffer (0.05 M Tris-HCl (pH 7.5),0.15 M NaCl,1% v/v Nonidet P-
40,1% w/v Na deoxycholate,1% protease inhibitor cocktail) or 1% Triton Buffer
(50 mM Tris–HCl (pH 7.5), 150 mM NaCl and 1% Triton-X-100, supplemented
with 1% protease inhibitor cocktail (Sigma)). The lysates were cleared by
centrifugation at 13,000 3 g for 15 min. The protein concentration of the lysates was
determined using bicinchoninic acid kit (Sigma), and equal amount of protein lysates
were loaded and were separated by SDS-PAGE, immunoblotted with the indicated
antibodies and visualized by chemiluminescence reagent SuperSignal (Thermo
Fischer Scientific, San Jose, CA). In most of the data in main text, gels have been
cropped for clarity; the bands were confirmed by the comparison with full-length gel
images (Supplementary Figure S2–S4) and molecular weight.
Quantitative real-time RT-PCR analysis. Total RNA was isolated from cells with
RNAiso Plus (TaKaRa, Japan) according to the manufacturer’s instruction. Q-RT-
PCR analysis for the indicated nucleotides and internal control 18S ribosomal RNA
(18S rRNA) were carried out with SYBR Green Master Mix (TaKaRa, Japan)
following the manufacturer’s instructions. The threshold cycle values for each gene
amplification were normalized by subtracting the threshold cycle value calculated for
18S rRNA (internal control). The oligonucleotide primers used in the Q-RT-PCR are
as follows: human STT3A (forward 59-GTGTGGACCGTGAAGGTTCTC-39 and
reverse 59-ATCCTGACCAGCCAATGTTCTG-39), human STT3B (forward 59-
AATCCACCTGTGGAGGACAGC-39 and reverse 59-TGTGACCCAGGTA-
CAGTGGAC-39), human 18S rRNA (forward 59-CGGCTACCACATCCAAGGAA-
39 and reverse 59-GCTGGAATTACCGCGGCT-39).
Immunoprecipitation. Confluent (90–100%) cells grown on 60-mm dishes were
lysed by gentle rotation in 500 ml of digitonin buffer (50 mM Tris–HCl, 150 mM
NaCl, 1% digitonin, and 1% protease inhibitor cocktail) for 2 hr at 4uC and
centrifuged at 15,000 3 g for 10 min at 4uC. The supernatant was gently rotated for
2 hr at 4uC with primary antibodies, followed by the additional incubation with
protein G-SepharoseH 4 Fast Flow for 1 hr at 4uC. Immune complexes were
precipitated and washed three times with 1 ml of digitonin wash buffer (50 mM Tris–
HCl, 150 mM NaCl, 0.1% digitonin, and 1% protease inhibitor cocktail).
Immunoprecipitated proteins were eluted for 30 min at 37uC with 23 concentrated
loading buffer and analyzed by Immunoblotting.
Analysis of protein stability and enzymatic digestion of N-glycosylation. For
evaluation of protein stability in the cells, CHX chase experiment was performed as
previously described. Briefly, plasmids- and/or siRNA-transfected cells were treated
with CHX (50 mM) for the time periods indicated and lysed and analyzed by
immunoblotting. For the Glycosidase digestion, cell lysates were incubated with Endo
H (500 U) and PNGase F (500 U) for 2 hr at 37uC. The density of the bands was
quantified using Image Gauge software (version 4.23; Fujifilm).
Pulse-chase experiments. Cells were incubated with methionine/cysteine-free
DMEM (Invitrogen) for 30 min. Cells were then pulse-labeled with 100 mCi/ml
EXPRE35S35S protein labeling Mix (PerkinElmer Life & Analytical Sciences, MA) for
5, 10, 15 or 30 min and chased in fresh complete medium containing 5 mM
methionine and cysteine for the indicated times. Cells were lysed in 1% Triton Buffer
containing 1% protease inhibitor cocktail and subjected to immunoprecipitation with
anti-HA or c-Myc antibody. Radioactivity was analyzed by BAS imaging plate
scanner (BAS-2000; Fujifilm, Japan) and quantified using Image Gauge software
(version 3.4; Fujifilm, Japan).
Statistical analysis. For quantitative analysis, most of the result represents the mean
6 SEM performed in triplicate and the data were analyzed by either Student’s t-test or
one-way ANOVA with Dunnett’s test (JMP software, SAS Institute) as indicated in
each figure legend.
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